miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma - PubMed (original) (raw)

. 2013 Oct;34(10):2231-9.

doi: 10.1093/carcin/bgt184. Epub 2013 May 28.

Affiliations

• PMID: 23715501
• DOI: 10.1093/carcin/bgt184

miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma

H W Z Khella et al. Carcinogenesis. 2013 Oct.

Abstract

MicroRNAs (miRNAs) play a crucial role in tumor progression and metastasis. We, and others, recently identified a number of miRNAs that are dysregulated in metastatic renal cell carcinoma compared with primary renal cell carcinoma. Here, we investigated three miRNAs that are significantly downregulated in metastatic tumors: miR-192, miR-194 and miR-215. Gain-of-function analyses showed that restoration of their expression decreases cell migration and invasion in renal cell carcinoma cell line models, whereas knockdown of these miRNAs resulted in enhancing cellular migration and invasion abilities. We identified three targets of these miRNAs with potential role in tumor aggressiveness: murine double minute 2, thymidylate synthase, and Smad Interacting protein 1/zinc finger E-box binding homeobox 2. We observed a convergent effect (the same molecule can be targeted by all three miRNAs) and a divergent effect (the same miRNA can control multiple targets) for these miRNAs. We experimentally validated these miRNA-target interactions using three independent approaches. First, we observed that miRNA overexpression significantly reduces the mRNA and protein levels of their targets. In the second, we observed significant reduction of the luciferase signal of a vector containing the 3'UTR of the target upon miRNA overexpression. Finally, we show the presence of inverse correlation between miRNA changes and the expression levels of their targets in patient specimens. We also examined the prognostic significance of miR-215 in renal cell carcinoma. Lower expression of miR-215 is associated with significantly reduced disease-free survival time. These findings were validated on an independent data set from The Cancer Genome Atlas. These results can pave the way to the clinical use of miRNAs as prognostic markers and therapeutic targets.

PubMed Disclaimer

Similar articles

• miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215.
  White NM, Khella HW, Grigull J, Adzovic S, Youssef YM, Honey RJ, Stewart R, Pace KT, Bjarnason GA, Jewett MA, Evans AJ, Gabril M, Yousef GM. White NM, et al. Br J Cancer. 2011 Nov 22;105(11):1741-9. doi: 10.1038/bjc.2011.401. Epub 2011 Oct 27. Br J Cancer. 2011. PMID: 22033272 Free PMC article.
• microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis.
  Wang X, Chen X, Wang R, Xiao P, Xu Z, Chen L, Hang W, Ruan A, Yang H, Zhang X. Wang X, et al. Oncol Rep. 2013 Aug;30(2):643-50. doi: 10.3892/or.2013.2530. Epub 2013 Jun 7. Oncol Rep. 2013. PMID: 23754305
• Cooperative Effect of miR-141-3p and miR-145-5p in the Regulation of Targets in Clear Cell Renal Cell Carcinoma.
  Liep J, Kilic E, Meyer HA, Busch J, Jung K, Rabien A. Liep J, et al. PLoS One. 2016 Jun 23;11(6):e0157801. doi: 10.1371/journal.pone.0157801. eCollection 2016. PLoS One. 2016. PMID: 27336447 Free PMC article.
• MicroRNAs and their target gene networks in renal cell carcinoma.
  Redova M, Svoboda M, Slaby O. Redova M, et al. Biochem Biophys Res Commun. 2011 Feb 11;405(2):153-6. doi: 10.1016/j.bbrc.2011.01.019. Epub 2011 Jan 11. Biochem Biophys Res Commun. 2011. PMID: 21232526 Review.
• MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis.
  Gu L, Li H, Chen L, Ma X, Gao Y, Li X, Zhang Y, Fan Y, Zhang X. Gu L, et al. Oncotarget. 2015 Oct 20;6(32):32545-60. doi: 10.18632/oncotarget.5324. Oncotarget. 2015. PMID: 26416448 Free PMC article. Review.

Cited by

• miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
  Khella HWZ, Butz H, Ding Q, Rotondo F, Evans KR, Kupchak P, Dharsee M, Latif A, Pasic MD, Lianidou E, Bjarnason GA, Yousef GM. Khella HWZ, et al. Mol Ther. 2015 Nov;23(11):1748-1758. doi: 10.1038/mt.2015.129. Epub 2015 Jul 23. Mol Ther. 2015. PMID: 26201448 Free PMC article.
• A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.
  Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AK. Wu SY, et al. Nat Commun. 2016 Apr 4;7:11169. doi: 10.1038/ncomms11169. Nat Commun. 2016. PMID: 27041221 Free PMC article.
• Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer.
  Prislei S, Martinelli E, Zannoni GF, Petrillo M, Filippetti F, Mariani M, Mozzetti S, Raspaglio G, Scambia G, Ferlini C. Prislei S, et al. Oncotarget. 2015 Aug 7;6(22):18966-79. doi: 10.18632/oncotarget.3943. Oncotarget. 2015. PMID: 26136338 Free PMC article.
• Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
  Damayanti NP, Budka JA, Khella HWZ, Ferris MW, Ku SY, Kauffman E, Wood AC, Ahmed K, Chintala VN, Adelaiye-Ogala R, Elbanna M, Orillion A, Chintala S, Kao C, Linehan WM, Yousef GM, Hollenhorst PC, Pili R. Damayanti NP, et al. Clin Cancer Res. 2018 Dec 1;24(23):5977-5989. doi: 10.1158/1078-0432.CCR-18-0269. Epub 2018 Jul 30. Clin Cancer Res. 2018. PMID: 30061365 Free PMC article.
• Nighttime light exposure enhances Rev-erbα-targeting microRNAs and contributes to hepatic steatosis.
  Borck PC, Batista TM, Vettorazzi JF, Soares GM, Lubaczeuski C, Guan D, Boschero AC, Vieira E, Lazar MA, Carneiro EM. Borck PC, et al. Metabolism. 2018 Aug;85:250-258. doi: 10.1016/j.metabol.2018.05.002. Epub 2018 May 8. Metabolism. 2018. PMID: 29751019 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program